Manufacturer record
Alifecare Formulation: regulatory record
Last checked 3 November 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
4 batches manufactured by Alifecare Formulation (Himachal Pradesh) were declared Not of Standard Quality in July 2025. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Most recent flagged batch: AFC2411056, Gabapentin Capsules IP 300mg. (Pebammyl-3G) (exp Oct 2026). State Drugs Laboratory, Punjab (state lab) found it not of standard quality: The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 65.02% of labelled claim against Q value. Listed in the July 2025 alert.
Records by type
4 records linked to Alifecare Formulation in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Gabapentin Capsules IP 300mg. (Pebammyl-3G) | Batch AFC2411056Mfg Nov 2024 · Exp Oct 2026 | The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 65.02% of labelled claim against Q value of NLT 80% of labelled claim.Labelling | State Drugs Laboratory, PunjabState lab | Jul 2025 |
| Gabapentin Capsules IP 300mg. (Pebammyl-3G) | Batch AFC2501028Mfg Jan 2025 · Exp Dec 2026 | The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 68.50% of labelled claim against Q value of NLT 80% of labelled claim.Labelling | State Drugs Laboratory, PunjabState lab | Jul 2025 |
| Gabapentin Capsules IP 300mg. (Pebammyl-3G) | Batch AFC2501029Mfg Jan 2025 · Exp Dec 2026 | The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 68.88% of labelled claim against Q value of NLT 80% of labelled claim.Labelling | State Drugs Laboratory, PunjabState lab | Jul 2025 |
| Gabapentin Capsules IP 300mg. (Pebammyl-3G) | Batch AFC2502059Mfg Feb 2025 · Exp Jan 2027 | The sample does not conform to claim as per I.P. 2022 even at Stage-III as the average release is 71.22% of labelled claim against Q value of NLT 80% of labelled claim.Labelling | State Drugs Laboratory, PunjabState lab | Jul 2025 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.